Dr Robotham is the Public Health England (PHE) Lead for the Organisational Change, Sustainability and Evalution theme of the National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance. Dr Robotham directs the research in the theme with Professor Rifat Atun the Imperial College Lead.
Dr Robotham currently leads the full programme of healthcare associated infections and antimicrobial resistance (HCAI & AMR) modelling and economics research within the Modelling and Economics Unit, Public Health England. She has worked in the field of modelling the transmission and control of HCAI & AMR for 10 years. Her research focuses on the development of mathematical models to explore the transmission dynamics and uses these analytic techniques to further understand the epidemiology of HCAI & AMR and to estimate the effectiveness and cost-effectiveness of prevention and control strategies.
Dr Robotham is experienced in healthcare policy development. She has led and continues to lead a number of research projects including the European Commission consortium Mastering hOSpital Antimicrobial Resistance in Europe (MOSAR), the Resistance in Gram-Negative Organisms: Studying Intervention Strategies. RGNOSIS Project and the ‘Assessment and cost-effectiveness evaluation of MRSA interventions in Australian ICUs’ Project
Dr Robotham also lectures on modelling and health economics at the London School of Hygiene and Tropical Medicine on the MSc ‘Modelling and the Dynamics of Infectious Diseases’ and short course ‘Introduction to Infectious Disease Modelling and Its Applications’, and on the CIPM, Imperial College MSc ‘Infection Management for Pharmacists’ and ‘Infection’, as well as on the ‘Health Economics Day’ for all PHE staff.
Dr Robotham has been an expert member of the Governmental Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections (ARHAI) since 2011, and is currently a member of the Department of Health’s Antimicrobial Resistance Strategy Analytical Working Group, as well as the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Oversight Group. She has been a member of the Executive Advisory Group for the Technology Strategy Board’s Innovation Platform on the Detection and Identification of Infectious Agents.